Employees talking

公司新闻

牛津免疫聚焦系列报道1——结核病（TB）仍然是一个严重的全球公共卫生问题
performance T-SPOT.TB test

Oxford Immunotec Presents Data on the Use of T-SPOT®.TB Test in Children over the Age of 2 to The Korean Society of Pediatric Infectious Diseases
Employee health T-SPOT.TB test

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study to Investigate the T Cell Response to SARS-CoV-2 Infection
physicians T-SPOT.TB test doctor xray

Oxford Immunotec’s T-SPOT.COVID Test is Used in the COV-AD Clinical Study to Investigate the Immunological Response to SARS-CoV-2 Infection in Patients with Primary and Secondary Antibody Deficiency
Laboratories T-SPOT.TB test

Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups
Physicians T-SPOT.TB test

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses
Oxford Immunotec logo

Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea

Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses
T-SPOT.CMV box Oxford Immunotec

New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19

英国公共卫生部和Oxford Immunotec联合发布数据，揭示SARS-CoV-2反应性T细胞与预防COVID-19有关

Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® Discovery™ SARS-CoV-2 Test

Oxford Immunotec Announces Food and Drug Administration (FDA) Clearance of the T-SPOT®.TB Test for Use in Pediatrics Over the Age of Two
dangerous virus outbreak

Oxford Immunotec Announces Donation in Support of Coronavirus Testing Efforts to Help Differentiate Tuberculosis from the COVID-19

Oxford Immunotec releases the T-SPOT® 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2

Oxford Immunotec Announces Agreement with Stop TB Partnership – Global Drug Facility (GDF) to Provide Access to the T-SPOT®.TB Test for 100+ TB Burden Countries

Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 is Published by PHE and Oxford Immunotec
Oxford Immunotec building exterior

Oxford Immunotec Reports First Quarter 2020 Financial Results
Oxford Immunotec logo

Oxford Immunotec Reports First Quarter 2020 Financial Results

Oxford Immunotec announces successful re-registration of the T-SPOT®.TB test in China